The evaluation and optimal use of rituximab in lymphoid malignancies

References

• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523–531.
   Google Scholar
• Alexander DD. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:1–39.
   Google Scholar
• American Cancer Society. Cancer facts and figures 2011. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003067-pdf.pdf. Accessed November 30, 2011.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. Semin Radiat Oncol. 2007;17(3):198–205.
   Web of Science ®Google Scholar
• Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med. 2008;132:118–1124.
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat indolent lymphoma. Blood. 2007;109(11):4617–4626.
   Web of Science ®Google Scholar
• Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13(3):279–287.
   PubMed Web of Science ®Google Scholar
• CLL Trialists ’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91(10):861–868.
   PubMed Web of Science ®Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia. 2002;16(6):1015–1027.
   Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750–1757.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96(8):2723–2729.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine pluscyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885–891.
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010;28(11):1861–1869.
   Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny A, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445–1476.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–445.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140–174.
   PubMedGoogle Scholar
• Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107–114.
   PubMed Web of Science ®Google Scholar
• Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278(43):42427–42434.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol. 2003;123(5):850–857.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12 Suppl 2:S1–S4.
   Google Scholar
• Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008;13(9):954–966.
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chapero L, et al. In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101(3):949–954.
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644–1652.
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood. 2000;95(12):3900–3908.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99(3):1038–1043.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis. Oncogene. 2007;26(42):6184–6193.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87(1):33–43.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials. 2008;3(1):22–30.
   Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(9):995–1001.
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007;62(1):43–52.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15(10):3266–3274.
   PubMed Web of Science ®Google Scholar
• Maloney D, Grillo-Lopez AJ, Link BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1999;10(6):655–661.
   PubMed Web of Science ®Google Scholar
• Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies. 2010;19(1):7–13.
   Google Scholar
• Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. TherDrugMonit. 2005;27(6):785–792.
   Google Scholar
• Mangel J, Buckstein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol. 2003;14(5):758–765.
   Web of Science ®Google Scholar
• Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5 Suppl 1:S37–S47.
   Google Scholar
• Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G. Model-based design of rituximab dosage optimisation in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. LeukLymphoma. 2006;47(6):998–1005.
   PubMed Web of Science ®Google Scholar
• Blasco H, Chatelut E, de Bretagne IB, et al. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol. 2009;23(5):601–608.
   PubMed Web of Science ®Google Scholar
• Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2002;29(10):1276–1282.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803–843.
   PubMed Web of Science ®Google Scholar
• Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol. 2001;74(1):70–75.
   Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. J Clin Oncol. 2010;28:S15.
   Web of Science ®Google Scholar
• Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ Jr. Hepatitis B reactivation and rituximab in the oncology practice. Oncologist. 2010;15(10):1113–1121.
   Web of Science ®Google Scholar
• Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90(10):1219–1223.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. 2010;28(34):5097–5100.
   PubMed Web of Science ®Google Scholar
• Precupanu CM, Girodet J, Mariani P, et al. Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation. Am J Hematol. 2009;84(2):127–128.
   Web of Science ®Google Scholar
• Song KW, Mollee P, Patterson B, Brien W, Crump M. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002;119(1):125–127.
   PubMed Web of Science ®Google Scholar
• Mawhorter SD, Sierk A, Staugaitis SM, et al. Fatal West Nile Virus infection after rituximab/fludarabine – induced remission for non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma. 2005;6(3):248–250.
   Google Scholar
• Tuccori M, Focosi D, Blandizzi C, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15(11):1214–1219.
   PubMed Web of Science ®Google Scholar
• Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy – rare but there! Leuk Lymphoma. 2009;50(7):1083–1095.
   PubMed Web of Science ®Google Scholar
• Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Trumper L, von Schilling C, et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. Ann Hematol. 2007;86(2):81–87.
   Web of Science ®Google Scholar
• Lunning M, Armitage JO. The curability of follicular lymphoma. Transfus Apher Sci. 2007;37(1):31–35.
   Web of Science ®Google Scholar
• Dreyling M; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5: v181–v183.
   Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–1423.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607–1614.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–2858.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–4008.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103(12):4416–4423.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088–1095.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248–255.
   PubMedGoogle Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927–1932.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19(2):389–397.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–3688.
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol. 2007;86(2):107–115.
   Web of Science ®Google Scholar
• Hess G, Flohr T, Kolbe K, et al. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma. Ann Hematol. 2006;85(11):769–779.
   Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-Cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: First interim analysis on 200 patients. CORAL Study. Blood. 2007;110(11):517.
   Web of Science ®Google Scholar
• Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26(19):3166–3175.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23(4):705–711.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984–1992.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High Rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013–7023.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and metaanalysis. J Natl Cancer Inst. 2007;99(9):706–714.
   PubMed Web of Science ®Google Scholar
• Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell lymphoma (MCL). (abstract). Blood. 2004;104 Suppl 1: S169:584.
   Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced mantle cell lymphoma. J Clin Oncol. 2009;27(4):511–518.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808–4816.
   PubMed Web of Science ®Google Scholar
• Forstpointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064–3071.
   Web of Science ®Google Scholar
• Hoerr AL, Gao F, Hidalgo JT, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22(22):4561–4566.
   PubMed Web of Science ®Google Scholar
• Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007;92(1):42–49.
   Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, e al; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–4008.
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E, et al. Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002;69(3):129–134.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8):2165–2170.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153–2164.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, et al; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21(9):1746–1751.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, O’Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2011;117(14):3182–3186.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6–14.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, DelPrincipe MI, Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer. 2005;104(12):2743–2752.
   Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100(9):3115–3120.
   PubMed Web of Science ®Google Scholar
• Byrd J, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49–53.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349–1355.
   PubMed Web of Science ®Google Scholar
• Gerrie AS, Toze CL, Ramadan KM, et al. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2010;10(10):1529–1543.
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070–4078.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–4088.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):373–380.
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(4):498–503.
   Web of Science ®Google Scholar
• Robak T. Improving FCR immunochemotherapy in CLL. Blood. 2010;115(3):437–438.
   Web of Science ®Google Scholar
• Hillmen P, Cohen DR, Cocks K, et al. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol. 2011;152(5):570–578.
   Web of Science ®Google Scholar
• Faderl S, Wierda W, O’Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res. 2010;34(3):284–288.
   Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27(27):4578–4584.
   Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010;115(3):489–495.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016–3024.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Keating MJ, O’Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062–2068.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24(10):1575–1581.
   Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405–411.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109(11):2291–2298.
   PubMed Web of Science ®Google Scholar
• Reynolds C, Di Bella N, Lyons RM, et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Grzybowska-lzydorczyk O, Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol. 2007;79(2):107–113.
   Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48(12):2412–2417.
   PubMed Web of Science ®Google Scholar
• Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23(10):1779–1789.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–3566.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood. 2009;114:89:205.
   Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45(11):2269–2273.
   PubMed Web of Science ®Google Scholar
• Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110–2118.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer. 2010;116(10):2360–2365.
   Web of Science ®Google Scholar
• Tadmor T, Polliack A. Rituximab in space: intrapleural and other novel routes of administration for lymphomas and lymphoid leukemias. Leuk Lymphoma. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Keating M, O’Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 2000;27(6 Suppl 12):86–90.
   Web of Science ®Google Scholar
• Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica. 2010;95(2):329–332.
   PubMed Web of Science ®Google Scholar
• Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006 ;177(10):7435–7443.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Rodríguez-Romo LN, González-Llano O. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol. 2009;144(5):794–795.
   Web of Science ®Google Scholar
• Schmidt HH, Renner H, Linkesch W. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL. Haematologica. 2004;89(11):ECR39
   Google Scholar
• Law MF, Yip SF, Poon WL, et al. Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas. Leuk Lymphoma. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin’s lymphoma. Ann Hematol. 2002;81(7):405–406.
   Web of Science ®Google Scholar
• Crysandt M, Neumann B, Das M. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol. 2007;79(6):546–549.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves Rituxan to treat chronic lymphocytic leukemia. Available from: http://www.fda. gov/newsevents/newsroom/pressannouncements/ucm201069.htm. Accessed May 18, 2011.
   Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Bio Drugs. 2011;25(1):13–25.
   Google Scholar
• Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther. 2008;10(3):294–309.
   Google Scholar
• Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin InvestigDrugs. 2009;10(6):588–596.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi50–54.
   Google Scholar
• Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi59-vi63.
   Web of Science ®Google Scholar